* Tempest Therapeutics Inc reported a quarterly adjusted loss of 38 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -63 cents. The mean expectation of five analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -43 cents to -32 cents per share.
* Reported revenue was zero; analysts expected zero.
* Tempest Therapeutics Inc's reported EPS for the quarter was a loss of 38 cents.
* The company reported a quarterly loss of $7.49 million.
* Tempest Therapeutics Inc shares had fallen by 15.0% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Tempest Therapeutics Inc is $13.00 This summary was machine generated from LSEG data March 20 at 11:59 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.39 -0.38 Beat
Sep. 30 2023 -0.57 -0.48 Beat
Jun. 30 2023 -0.52 -0.54 Missed
Mar. 31 2023 -0.64 -0.55 Beat
Comments